197 related articles for article (PubMed ID: 37625594)
41. Emerging Concepts in Hematopoietic Stem Cell Transplantation-Associated Renal Thrombotic Microangiopathy and Prospects for New Treatments.
Wanchoo R; Bayer RL; Bassil C; Jhaveri KD
Am J Kidney Dis; 2018 Dec; 72(6):857-865. PubMed ID: 30146419
[TBL] [Abstract][Full Text] [Related]
42. Intestinal thrombotic microangiopathy: a distinct entity in the spectrum of graft-versus-host disease.
Gavriilaki E; Sakellari I; Karafoulidou I; Pasteli N; Batsis I; Mallouri D; Lazaridou A; Iskas M; Vardi A; Papalexandri A; Tsompanakou A; Papaemmanouil S; Ilias A; Anagnostopoulos A
Int J Hematol; 2019 Nov; 110(5):529-532. PubMed ID: 31586304
[TBL] [Abstract][Full Text] [Related]
43. Incidence, Risk Factors for and Outcomes of Transplant-Associated Thrombotic Microangiopathy.
Epperla N; Li A; Logan B; Fretham C; Chhabra S; Aljurf M; Chee L; Copelan E; Freytes CO; Hematti P; Lazarus HM; Litzow M; Nishihori T; Olsson RF; Prestidge T; Saber W; Wirk B; Yared JA; Loren A; Pasquini M
Br J Haematol; 2020 Jun; 189(6):1171-1181. PubMed ID: 32124435
[TBL] [Abstract][Full Text] [Related]
44. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis.
Higham CS; Collins G; Shimano KA; Melton A; Kharbanda S; Winestone LE; Huang JN; Dara J; Long-Boyle JR; Dvorak CC
Blood Adv; 2021 Apr; 5(8):2106-2114. PubMed ID: 33877298
[TBL] [Abstract][Full Text] [Related]
45. Transplant-Associated Thrombotic Microangiopathy in the Context of Allogenic Hematopoietic Stem Cell Transplantation: Where We Stand.
Lazana I
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674666
[TBL] [Abstract][Full Text] [Related]
46. Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?
Jodele S; Laskin BL; Goebel J; Khoury JC; Pinkard SL; Carey PM; Davies SM
Transfusion; 2013 Mar; 53(3):661-7. PubMed ID: 22804695
[TBL] [Abstract][Full Text] [Related]
47. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal changes in body mass and composition in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem-cell transplantation.
Inaba H; Yang J; Kaste SC; Hartford CM; Motosue MS; Chemaitilly W; Triplett BM; Shook DR; Pui CH; Leung W
J Clin Oncol; 2012 Nov; 30(32):3991-7. PubMed ID: 23032628
[TBL] [Abstract][Full Text] [Related]
49. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.
Jodele S; Laskin BL; Dandoy CE; Myers KC; El-Bietar J; Davies SM; Goebel J; Dixon BP
Blood Rev; 2015 May; 29(3):191-204. PubMed ID: 25483393
[TBL] [Abstract][Full Text] [Related]
50. New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Dandoy CE; Myers KC; El-Bietar J; Nelson A; Wallace G; Laskin BL
Transfus Apher Sci; 2016 Apr; 54(2):181-90. PubMed ID: 27156964
[TBL] [Abstract][Full Text] [Related]
51. [Clinical analysis of sirolimus as an alternative GVHD prophylaxis for patients with kidney injury undergoing allo-HSCT].
Sun W; Ma R; He Y; Bai L; Chen YY; Chen Y; Zhang YY; Wang JZ; Chen H; Zhang XH; Xu LP; Wang Y; Huang XJ; Sun YQ
Zhonghua Nei Ke Za Zhi; 2023 Dec; 62(12):1444-1450. PubMed ID: 38044071
[No Abstract] [Full Text] [Related]
52. Circulating dsDNA, endothelial injury, and complement activation in thrombotic microangiopathy and GVHD.
Gloude NJ; Khandelwal P; Luebbering N; Lounder DT; Jodele S; Alder MN; Lane A; Wilkey A; Lake KE; Litts B; Davies SM
Blood; 2017 Sep; 130(10):1259-1266. PubMed ID: 28705839
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Biomarkers for Thrombotic Microangiopathy after Acute Graft-versus-Host Disease: A Nested Case-Control Study.
Li A; Bhatraju PK; Chen J; Chung DW; Hilton T; Houck K; Pao E; Weiss NS; Lee SJ; Davis C; Schmidt MJ; Lopez JA; Liles WC; Dong JF; Hingorani SR
Transplant Cell Ther; 2021 Apr; 27(4):308.e1-308.e8. PubMed ID: 33836868
[TBL] [Abstract][Full Text] [Related]
54. Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation.
Yu J; Parasuraman S; Shah A; Weisdorf D
Curr Med Res Opin; 2019 Jun; 35(6):983-988. PubMed ID: 30461314
[TBL] [Abstract][Full Text] [Related]
55. Serum neutrophil extracellular trap levels predict thrombotic microangiopathy after allogeneic stem cell transplantation.
Arai Y; Yamashita K; Mizugishi K; Watanabe T; Sakamoto S; Kitano T; Kondo T; Kawabata H; Kadowaki N; Takaori-Kondo A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1683-9. PubMed ID: 24055655
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic Plasma Exchange does not Improve Renal Function in Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy: An Institutional Experience.
Sartain S; Shubert S; Wu MF; Srivaths P; Teruya J; Krance R; Martinez C
Biol Blood Marrow Transplant; 2019 Jan; 25(1):157-162. PubMed ID: 30144562
[TBL] [Abstract][Full Text] [Related]
57. Abnormal echocardiography 7 days after stem cell transplantation may be an early indicator of thrombotic microangiopathy.
Dandoy CE; Davies SM; Hirsch R; Chima RS; Paff Z; Cash M; Ryan TD; Lane A; El-Bietar J; Myers KC; Jodele S
Biol Blood Marrow Transplant; 2015 Jan; 21(1):113-8. PubMed ID: 25300868
[TBL] [Abstract][Full Text] [Related]
58. Incidence and Risk Factors of Transplantation-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.
Van Benschoten V; Roy C; Gupta R; Ouellette L; Hingorani S; Li A
Transplant Cell Ther; 2022 May; 28(5):266.e1-266.e8. PubMed ID: 35042011
[TBL] [Abstract][Full Text] [Related]
59. Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation.
Mezö B; Horváth O; Sinkovits G; Veszeli N; Kriván G; Prohászka Z
Front Med (Lausanne); 2020; 7():569291. PubMed ID: 33117830
[TBL] [Abstract][Full Text] [Related]
60. D-dimer and sinusoidal obstructive syndrome-novel poor prognostic features of thrombotic microangiopathy in children after hematopoietic cellular therapy in a single institution prospective cohort study.
Schoettler ML; French K; Harris A; Bryson E; Deeb L; Hudson Z; Obordo J; Chandrakasan S; Parikh S; Watkins B; Stenger E; Qayed M; Chonat S; Westbrook A; Switchenko J; Williams KM
Am J Hematol; 2024 Mar; 99(3):370-379. PubMed ID: 38164997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
